CN201作为一种新型的CD3xCD19双特异性抗体,通过同时结合T细胞和B细胞,激活T细胞介导的免疫反应,从而特异性地清除白血病细胞。 2024年美国临床肿瘤学会年会(ASCO)上,中国医学科学院血液研究所王迎教授团队报告了CN201的I期临床研究结果,...
参考文献: Ying Wang, Qingsong Yin, Jinhai Ren, et al. Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. 2024 ...
CN201 is a novel CD19-targeting T-cell-engaging IgG4 bispecific antibody. This phase I study is to investigate the safety, tolerability and preliminary efficacy of CN201 in B-ALL (ClinicalTrials.gov identifier: NCT05579132). The data from the dose escalation and expansion of the ongoing ...
Surface DR5 is analyzed similarly with an antibody from Imgenex. For sub-G1content and cell cycle profile analysis, all cells are pelleted and ethanol-fixed, followed by staining with propidium iodide in the presence of RNase. Cell viability assays are carried out in 96-well black-walled ...
and Curon Biopharmaceutical (Curon), a privately held biotechnology company, today announced that the companies have entered into a definitive agreement under whichMerck, through a subsidiary, has agreed to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of...
默沙东,merck。7亿美金首付收购同润资产。 license out! CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as...
CAS号: 英文名: C20orf201 antibody (PE) 英文别名: C20orf201 antibody (PE) 中文名: 中文别名: CBNumber: CB06006305 分子式: 分子量: 0 MOL File: Mol file 化学性质 安全信息 用途 供应商 1 C20orf201 antibody (PE)化学性质
C6orf201 antibody (FITC) 英文别名: C6orf201 antibody (FITC) 中文名: 中文别名: CBNumber: CB86004408 分子式: 分子量: 0 MOL File: Mol file 化学性质安全信息用途供应商1 C6orf201 antibody (FITC)化学性质 安全信息 C6orf201 antibody (FITC)性质、用途与生产工艺 ...
Guinea Pig Anti Connexin 43 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
近日,来自Denali Therapeutics Inc.的科学家在《Science Translational Medicine》上介绍了他们设计的双特异性抗体,称之为血脑屏障运输工具抗体(antibody transport vehicle,ATV)。这种抗体被认为可特异性地与大脑内皮细胞表面上表达的RMT受体结合,利用受体介导的胞吞效应(receptor-mediated transcytosis,RMT)穿过血脑屏障,极...